Al-Ruhaili Muna Salim, Al-Mahrouqi Haitham Hilal
Ophthalmology Residency Program, Oman Medical Specialty Board, Muscat, Sultanate of Oman.
Department of Ophthalmology, Al-Nahdha Hospital, Ministry of Health, Muscat, Sultanate of Oman.
Oman J Ophthalmol. 2025 Jun 24;18(2):205-207. doi: 10.4103/ojo.ojo_344_24. eCollection 2025 May-Aug.
The aim is to report corneal melting following intrastromal injection of antivascular endothelial growth factor (anti-VEGF), bevacizumab, for pre-existing corneal neovascularization. A 68-year-old male with a history of failed bilateral penetrating keratoplasties due to scarring from childhood measles and trachoma underwent right eye superficial keratectomy, intrastromal bevacizumab, and amniotic membrane transplant to control the neovascularization in an overseas center. A week later developed corneal melting. In conclusion, anti-VEGF can be used in controlling corneal neovascularization, albeit, is associated with risks such as delayed epithelial healing and corneal melting, particularly in those with limbal stem cell deficiency.
目的是报告在角膜基质内注射抗血管内皮生长因子(抗VEGF)贝伐单抗治疗既往存在的角膜新生血管后发生的角膜溶解情况。一名68岁男性,因儿童时期麻疹和沙眼瘢痕导致双侧穿透性角膜移植术失败,在海外一家中心接受了右眼浅表角膜切除术、角膜基质内贝伐单抗注射及羊膜移植,以控制新生血管。一周后发生了角膜溶解。总之,抗VEGF可用于控制角膜新生血管,尽管其与上皮愈合延迟和角膜溶解等风险相关,尤其是在那些存在角膜缘干细胞缺乏的患者中。